Women aged 18 to 45 in South Africa, Uganda, Malawi and Zimbabwe were involved in the trials. Women who were assigned the dapivirine ring showed a 27% - 30% relative reduction in HIV incidence. A surprising 56% reduction was seen in women older than 21 years of age.
Linda-Gail Bekker, one of the authors of the study, says: “We can really build on these important results. Globally women need options to protect themselves from HIV acquisition. The dapivirine vaginal ring is one such option.”
The study demonstrated that the vaginal ring was safe and effective for HIV prevention in women. This study is the first to demonstrate HIV protection from a sustained-release approach of an antiretroviral, which is considered a breakthrough.
With approximately 6,8 million people living with HIV in South Africa and nearly 60% being women – this is a female-controlled HIV prevention method that can potentially reduce new infections among women.
Researchers and health authorities now have to start the process of getting the ring approved in order to make it accessible and affordable to the public. It could be years before the ring joins other HIV prevention options such as condoms, oral pre-exposure prophylaxis and voluntary medical male circumcision (VMMC).
“As a country, we have the highest HIV burden in the world with approximately 400,000 new HIV infections annually. While these results of the vaginal ring trial are encouraging, it shouldn’t deter the public from making use of what we have available now. South Africa would benefit greatly from having more men circumcised, as this not only lowers the risk of HIV acquisition among men, but it also reduces the risk of men transmitting the infection, which ultimately protects women against exposure to HIV as well,” says Marina Rifkin, the public health specialist at CareWorks, an HIV management organisation..
